| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.86B | 26.69B | 24.22B | 18.54B | 13.57B | 7.34B |
| Gross Profit | 8.69B | 9.53B | 7.46B | 5.78B | 4.17B | 3.02B |
| EBITDA | 3.05B | 3.84B | 2.51B | 2.03B | 1.57B | 1.26B |
| Net Income | 1.18B | 1.70B | 1.39B | 1.15B | 892.41M | 667.02M |
Balance Sheet | ||||||
| Total Assets | 32.95B | 30.47B | 24.02B | 21.96B | 23.02B | 12.34B |
| Cash, Cash Equivalents and Short-Term Investments | 7.89B | 7.67B | 4.66B | 5.23B | 3.65B | 3.47B |
| Total Debt | 15.90B | 12.13B | 8.42B | 8.67B | 11.64B | 3.19B |
| Total Liabilities | 18.83B | 16.12B | 11.56B | 10.64B | 13.22B | 4.46B |
| Stockholders Equity | 13.53B | 13.78B | 12.27B | 11.09B | 9.80B | 7.88B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 185.31M | 73.83M | 3.78B | -8.16B | -3.82B |
| Operating Cash Flow | 0.00 | 435.30M | 452.64M | 4.36B | -7.31B | -3.57B |
| Investing Cash Flow | 0.00 | -1.37B | -376.36M | -427.07M | -1.64B | -253.80M |
| Financing Cash Flow | 0.00 | 1.94B | -554.26M | -3.13B | 9.31B | 3.28B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥49.26B | 6.41 | ― | 3.59% | 15.82% | 22.32% | |
76 Outperform | ¥57.87B | 34.25 | ― | 2.18% | 28.70% | 47.57% | |
69 Neutral | ¥56.70B | 7.44 | ― | 5.97% | 66.79% | 175.17% | |
66 Neutral | ¥45.88B | 10.75 | ― | 5.72% | 68.10% | 27.55% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
65 Neutral | ¥46.06B | 7.29 | ― | 2.49% | 33.64% | -0.28% | |
57 Neutral | ¥45.14B | 37.89 | ― | 0.54% | 3.47% | -32.39% |
SRE Holdings Corporation announced that its wholly owned subsidiary, MEDIX Co, Ltd., will distribute surplus dividends amounting to 600,600,000 yen to the parent company. This dividend income will be recorded as non-operating income in SRE Holdings’ non-consolidated financial results, with no impact on the consolidated financial results for the fiscal year ending March 31, 2026.
The most recent analyst rating on (JP:2980) stock is a Hold with a Yen3591.00 price target. To see the full list of analyst forecasts on SRE Holdings Corp. stock, see the JP:2980 Stock Forecast page.
SRE Holdings Corporation reported a significant decline in its financial performance for the three months ended June 30, 2025, with net sales dropping by 16.3% and operating profit plummeting by 89.1% compared to the same period last year. Despite the downturn, the company maintains its financial forecast for the fiscal year ending March 31, 2026, expecting a 31.1% increase in net sales and a 30.3% rise in operating profit, indicating a potential recovery and growth in the upcoming quarters.